All In Biotech

Drug Trial Radar · NCT00194519

Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission

Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples

Last checked: Nov 19, 2026Latest source record: Oct 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,408 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,408

Actual

Start

Nov 2004

Primary completion

Nov 2009

Study completion Mar 2010

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bill and Melinda Gates Foundation
First posted
Sep 19, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The University of Washington has received funding to conduct a proof-of-concept trial to assess the impact of suppression of genital herpes on HIV infectiousness. This study (the Partners in Prevention Study) will enroll HIV discordant heterosexual couples in which the HIV-infected partner is co-infected with herpes simplex virus type 2 (HSV-2) to test the efficacy of twice daily (bid) acyclovir (400 mg) given to the HIV-infected partner to prevent transmission to his/her HIV negative partner(s). This randomized, double-blind, placebo-controlled proof-of-concept trial will provide evidence for the efficacy of HSV-2 suppression with daily acyclovir on HIV transmission among HIV-discordant couples among whom the HIV-positive partner is also HSV-2 seropositive with CD4 \>250. The researchers hypothesis is that, by decreasing the frequency and amount of genital HIV shedding, standard doses of daily acyclovir 400 mg bid will reduce the rate of HIV transmission by 50% in HIV-discordant couples among whom the HIV-infected partner is HSV-2 positive. Under the study protocol version 4.1.1, 3000 HIV-discordant heterosexual couples in which the HIV-positive partner is HSV-2 positive and has a CD4 count \>250 will be recruited; participants will be followed for up to 2 years. A 4% per year HIV incidence in the placebo arm is assumed. The first study site began enrolling participants on 17 November 2005. As of September 2006, 14 sites in Eastern and Southern Africa had participated in recruiting the 2300 HIV-discordant couples enrolled to date.

Conditions

  • HIV Infection
  • Herpes Simplex, Genital
  • Sexually Transmitted Diseases

Interventions

  • Generic acyclovirDrug

    400 mg twice-daily oral

  • PlaceboDrug

    twice-daily oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sequence-verified HIV-transmission from index to partner participantTime frame: March 2009

Locations

13 sites in 7 countries. Site status is shown where the registry gives one.

  • Botswana-Harvard Partnership

    Gabarone, Botswana

  • Moi University - Indiana University

    Eldoret, Kenya

  • Kemri - Ucsf

    Kisumu, Kenya

  • University of Nairobi

    Nairobi, Kenya

  • Partners Study Thika Site

    Thika, Kenya

  • Projet San Francisco-Emory University

    Kigali, Rwanda

  • University of Cape Town

    Cape Town, South Africa

  • Perinatal HIV Research Unit, University of Witswatersrand

    Johannesburg, South Africa

  • Reproductive Health and HIV Research Unit

    Johannesburg, South Africa

  • Kilimanjaro Christian Medical College-Harvard University

    Moshi, Tanzania

  • Mulago Hospital - IDI

    Kampala, Uganda

  • Zambia-Emory HIV Research Project

    Lusaka, Zambia

  • Zambia-Emory HIV Research Project

    Ndola/Kitwe, Zambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.